Bedrijfsoverzicht
Soleno Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics specifically designed for the treatment of rare diseases, with its primary focus currently on Prader-Willi Syndrome. The company operates within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address unmet medical needs in niche therapeutic areas that often require significant research and development investment. In terms of scale, the entity currently holds a market capitalization of $2.72B while reporting annual revenue of $190.40M and employing 182 individuals. These valuation and revenue figures suggest that the market assigns a substantial premium to the company's intellectual property and pipeline potential, indicating a position where investor confidence is high despite the inherent risks associated with the early-to-mid stage biotechnology development cycle.
Financiële gezondheid
The financial performance of Soleno Therapeutics is characterized by a revenue of $190.40M over the trailing twelve months, which resulted in a net income of $20.48M and an EBITDA of $16.97M. The gap between the $190.40M in revenue and the $20.48M in net income reveals a cost structure where approximately 89% of sales are consumed by operating expenses, taxes, and interest, leaving a significant portion of gross revenue to cover the substantial costs of drug development and commercialization. The company generates a free cash flow of $48.27M, a figure that indicates strong financial flexibility allowing the firm to fund its research initiatives without immediate reliance on external equity financing or asset liquidation. Profitability is underscored by a gross margin of 98.6%, an operating margin of 44.1%, and a profit margin of 11.0%, where the high gross margin reflects the low cost of goods sold typical of pharmaceutical products, while the operating and profit margins demonstrate the company's ability to convert sales into operational profit before and after all expenses respectively. Regarding leverage, the company holds $305.47M in cash against $52.55M in debt, resulting in a debt-to-equity ratio of 11.68, which suggests a capital structure heavily reliant on equity financing rather than traditional debt, presenting a conservative stance on interest obligations. Liquidity is robust as evidenced by a current ratio of 5.80, indicating that the company possesses more than five times the current assets necessary to cover its short-term liabilities, thereby ensuring operational continuity. Management effectiveness is quantified by a return on equity of 6.0% and a return on assets of 2.1%, metrics that reveal the efficiency with which the company utilizes shareholder capital and total assets to generate net income, respectively.
Waarderingsbeoordeling
Valuation metrics for Soleno Therapeutics, Inc. show a trailing P/E ratio of 134.95 and a forward P/E of -23.19, a divergence that implies the market expects earnings to either contract significantly or that future earnings estimates have been adjusted downward relative to current profitability. The price-to-book ratio stands at 6.11, indicating that the market values the company at more than six times its net asset value, which suggests a significant premium assigned to its intangible assets such as patents and proprietary drug candidates. Alternative valuation measures include a price-to-sales ratio of 14.30 and an EV/EBITDA of 145.23, figures that suggest the market is willing to pay a high multiple for every dollar of sales and earnings generated, reflecting expectations of future growth once current product candidates reach full commercialization. Price volatility over the past year is captured by a 52-week high of $90.32 and a low of $29.43, meaning the stock currently trades at a level that requires calculation to determine its exact percentage distance from the highs or lows, though the wide spread highlights significant intraperiod price movement. The stock exhibits a beta of -2.81, a negative value that is highly unusual and indicates that the stock's price moves inversely to the broader market with extreme intensity, suggesting that Soleno's price action is driven by specific sector factors or sentiment rather than general market trends.
Growth & Income
Growth metrics for the trailing twelve months show revenue growth and earnings growth rates listed as N/A in the provided data, preventing a direct comparison of whether earnings are growing faster or slower than revenue based on the current fiscal year's change. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that Soleno reinvests all of its net income back into the business for research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is standard for biotechnology companies in the commercialization phase, where capital is prioritized for expanding the pipeline of novel therapeutics for rare diseases over providing immediate income to investors. Consequently, the overall growth and income profile is defined by a lack of current income generation through dividends and a focus on capital appreciation potential, where value is derived from the successful execution of the company's development plan and the eventual monetization of its lead product candidate, VYKAT XR.